Bluejay Diagnostics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $1.1M
- Price
- $0.9109
- % Change (Daily % change from the live per-ticker quote feed.)
- -3.02%
- Volume
- 120.3K
About
Bluejay Diagnostics, Inc. functions as a company specializing in medical diagnostic solutions. A key offering is their Symphony platform, an advanced technological system. This platform is composed of the Symphony analyzer, which skillfully orchestrates the processing of whole blood, the isolation of biomarkers, and the preparation of immunoassays using non-contact centrifugal force. It also includes the Symphony Cartridge, which comes pre-loaded with essential reagents and components. The company additionally provides the ALLEREYE diagnostic test, a convenient, on-site device for quickly identifying allergic conjunctivitis. Bluejay Diagnostics is also progressing with the development of Symphony IL-6 tests, intended for monitoring disease advancement in critical care environments. Furthermore, they are actively creating additional diagnostic tests for their Symphony platform, such as those aimed at detecting myocardial infarction (heart attack) and congestive heart failure. Bluejay Diagnostics, Inc. was founded in 2015 and is headquartered in Acton, Massachusetts.
Quick stats
Shares outstanding1.0M
Computed float921.1K
Float / shares89.0%
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001704287
Websitehttps://bluejaydx.com
AI Summary
AI-generated1/13
standardbullishearnings
Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization
Bluejay Diagnostics completed targeted enrollment of 750 patients in its SYMON-II pivotal clinical study, marking a key step toward a planned FDA 510(k) submission for the Symphony IL-6 test.
The company ended the second quarter with $9.6 million in cash, bolstered by $7.6 million in net proceeds from a private placement closed in June.
Management estimates current cash resources will fund operations into the second quarter of 2027, supporting the shift toward manufacturing readiness and commercialization activities.